Big change in market-access strategies, execs say

What's the biggest change for today's pharma executive? Market access strategies, according to a survey by Cegedim Dendrite. Forty percent cited it as the part of their business undergoing the biggest changes, while 20 percent chose sales-force restructuring. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.